首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations.
【2h】

Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations.

机译:鲍曼不动杆菌医院分离株的体外体外药敏性比较和九种抗菌药物组合的协同活性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The in vitro susceptibilities of 69 nosocomial Acinetobacter isolates were determined by the broth microdilution method. Fourteen (20%) isolates were resistant to at least two aminoglycosides and two extended-spectrum penicillins. Nine antimicrobial combinations were then tested for synergy against these 14 isolates by checkerboard titration: imipenem with ciprofloxacin, amikacin, and tobramycin and ampicillin-sulbactam, piperacillin-tazobactam, and ticarcillin-clavulanate with amikacin and tobramycin. Synergy was detected with one or more antimicrobial combinations against 9 of 14 (64%) isolates, partial synergy was detected with one or more combinations against all 14 isolates, and an additive effect alone was observed with two different combinations against two isolates. No antagonism was detected with any combination. Imipenem plus either amikacin or tobramycin resulted in a synergistic or partial synergistic response against all 14 isolates. Specific combinations showing synergy against A. baumannii isolates were imipenem with tobramycin (four isolates), imipenem with amikacin (three isolates), ampicillin-sulbactam with tobramycin (six isolates), ampicillin-sulbactam with amikacin (three isolates), and ticarcillin-clavulanate with tobramycin (one isolate). Genotyping by randomly amplified polymorphic DNA analysis showed that 9 of the 14 isolates were of one strain, 4 isolates were of a second strain, and the remaining isolate was of a different strain. Eight of 14 (57%) patients infected with resistant A. baumannii isolates died. Only 3 of 14 patients had received a therapeutic regimen which was tested for synergy. Clinical studies are needed to determine the significance of these findings.
机译:通过肉汤微量稀释法测定69株医院不动杆菌的体外药敏性。十四株(20%)分离株对至少两种氨基糖苷和两种广谱青霉素有抗药性。然后通过棋盘滴定测试了9种抗菌药物组合对这14种分离物的协同作用:亚胺培南与环丙沙星,阿米卡星和妥布霉素和氨苄青霉素-舒巴坦,哌拉西林-他唑巴坦和替卡西林-克拉维酸盐与阿米卡星和妥布霉素的协同作用。用一种或多种抗微生物组合对14种分离物中的9种检测出协同作用(64%),用一种或多种组合对14种分离物检测出部分协同作用,而用两种不同组合对两种分离物观察到单独的累加作用。任何组合均未检测到拮抗作用。亚胺培南加阿米卡星或妥布霉素对所有14种分离株产生协同或部分协同反应。在对抗鲍曼不动杆菌中显示协同作用的特定组合包括:亚胺培南与妥布霉素(四种分离物),亚胺培南与阿米卡星(三种分离物),氨苄西林-舒巴坦与妥布霉素(六种分离物),氨苄西林-舒巴坦与阿米卡星(三种分离物)和替卡西林-克拉维酸盐与妥布霉素(一种分离物)。通过随机扩增的多态性DNA分析进行的基因分型显示,这14个分离株中有9个属于一个菌株,有4个分离株属于第二个菌株,其余分离株属于另一个菌株。 14名感染耐药性鲍曼不动杆菌的患者中有8名(57%)死亡。 14名患者中只有3名接受了经过协同作用测试的治疗方案。需要进行临床研究以确定这些发现的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号